Our friends at the American Epilepsy Society released this alert.
FDA approved a GlaxoSmithKline supplemental new drug application to provide for addition of the following to the Adverse Reactions; Postmarketing Experience section of the Prescribing Information for several formulations of Lamictal (lamotrigine) tablets : “Renal and Urinary Disorders: Tubulointerstitial nephritis (has been reported alone and in association with uveitis).” Please see the approval letter and the PI for details.
